View Item 

Show simple item record

Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)
dc.contributor.authorPreiss, Daviden_US
dc.contributor.authorVeldhuisen, Dirk J.en_US
dc.contributor.authorSattar, Naveeden_US
dc.contributor.authorKrum, Henryen_US
dc.contributor.authorSwedberg, Karlen_US
dc.contributor.authorShi, Harryen_US
dc.contributor.authorVincent, Johnen_US
dc.contributor.authorPocock, Stuart J.en_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorZannad, Faiezen_US
dc.contributor.authorMcMurray, John J.V.en_US
dc.date.accessioned2014-03-05T18:19:00Z
dc.date.available2014-03-05T18:19:00Z
dc.date.issued2012-08en_US
dc.identifier.citationPreiss, David; Veldhuisen, Dirk J.; Sattar, Naveed; Krum, Henry; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram; Zannad, Faiez; McMurray, John J.V. (2012). "Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)." European Journal of Heart Failure 14(8): 909-915. <http://hdl.handle.net/2027.42/106098>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106098
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherDiabetesen_US
dc.subject.otherChronic Heart Failureen_US
dc.subject.otherEplerenoneen_US
dc.subject.otherPredictionen_US
dc.titleEplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22611047en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106098/1/ejhfhfs067.pdf
dc.identifier.doi10.1093/eurjhf/hfs067en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferenceKosmala W Przewlocka‐Kosmala M Szczepanik‐Osadnik H Mysiak A O'Moore‐Sullivan T Marwick TH A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, fibrosis markers in metabolic syndrome JACC Cardiovasc Imaging 2011 4 1239 1249en_US
dc.identifier.citedreferenceMacDonald MR Petrie MC Hawkins NM Petrie JR Fisher M McKelvie R Aguilar D Krum H McMurray JJ Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur Heart J 2008 29 1224 1240en_US
dc.identifier.citedreferencePreiss D Zetterstrand S McMurray JJ Ostergren J Michelson EL Granger CB Yusuf S Swedberg K Pfeffer MA Gerstein HC Sattar N Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program Diabetes Care 2009 32 915 920en_US
dc.identifier.citedreferenceTorp‐Pedersen C Metra M Charlesworth A Spark P Lukas MA Poole‐Wilson PA Swedberg K Cleland JG Di Lenarda A Remme WJ Scherhag A; COMET investigators. Effects of metoprolol and carvedilol on pre‐existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) Heart 2007 93 968 973en_US
dc.identifier.citedreferenceElliott WJ Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta‐analysis Lancet 2007 369 201 207en_US
dc.identifier.citedreferenceMcMurray JJ Holman RR Haffner SM Bethel MA Holzhauer B Hua TA Belenkov Y Boolell M Buse JB Buckley BM Chacra AR Chiang FT Charbonnel B Chow CC Davies MJ Deedwania P Diem P Einhorn D Fonseca V Fulcher GR Gaciong Z Gaztambide S Giles T Horton E Ilkova H Jenssen T Kahn SE Krum H Laakso M Leiter LA Levitt NS Mareev V Martinez F Masson C Mazzone T Meaney E Nesto R Pan C Prager R Raptis SA Rutten GE Sandstroem H Schaper F Scheen A Schmitz O Sinay I Soska V Stender S Tamás G Tognoni G Tuomilehto J Villamil AS Vozár J Califf RM Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 2010 362 1477 1490en_US
dc.identifier.citedreferenceYusuf S Ostergren JB Gerstein HC Pfeffer MA Swedberg K Granger CB Olofsson B Probstfield J McMurray JV Candesartan in Heart Failure‐Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure Circulation 2005 112 48 53en_US
dc.identifier.citedreferenceYamaji M Tsutamoto T Kawahara C Nishiyama K Yamamoto T Fujii M Horie M Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure Am Heart J 2010 160 915 921en_US
dc.identifier.citedreferenceMatsumoto S Takebayashi K Aso Y The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy Metabolism 2006 55 1645 1652en_US
dc.identifier.citedreferenceDavies JI Band M Morris A Struthers AD Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes Diabetologia 2004 47 1687 1694en_US
dc.identifier.citedreferenceSwaminathan K Davies J George J Rajendra NS Morris AD Struthers AD Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles Diabetologia 2008 51 762 768en_US
dc.identifier.citedreferencePolyzos SA Kountouras J Zafeiriadou E Patsiaoura K Katsiki E Deretzi G Zavos C Tsarouchas G Rakitzi P Slavakis A Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease J Renin Angiotensin Aldosterone Syst 2011 12 498 503en_US
dc.identifier.citedreferenceZannad F McMurray JJ Drexler H Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) Eur J Heart Fail 2010 12 617 622en_US
dc.identifier.citedreferenceZannad F McMurray JJ Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Pocock SJ Pitt B; EMPHASIS‐HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 2011 364 11 21en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention Diabetes Data and Trends 2009 available at: http://www.cdc.gov/diabetes/statistics/incidence/fig3.htm (last accessed 2 February 2012)en_US
dc.identifier.citedreferenceGarg R Hurwitz S Williams GH Hopkins PN Adler GK Aldosterone production and insulin resistance in healthy adults J Clin Endocrinol Metab 2010 95 1986 1990en_US
dc.identifier.citedreferenceCatena C Lapenna R Baroselli S Nadalini E Colussi G Novello M Favret G Melis A Cavarape A Sechi LA Insulin sensitivity in patients with primary aldosteronism: a follow‐up study J Clin Endocrinol Metab 2006 91 3457 3463en_US
dc.identifier.citedreferenceHeianza Y Hara S Arase Y Saito K Totsuka K Tsuji H Kodama S Hsieh SD Yamada N Kosaka K Sone H Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1) Diabetologia 2011 54 762 726en_US
dc.identifier.citedreferenceAksnes TA Kjeldsen SE Rostrup M Storset O Hua TA Julius S Predictors of new‐onset diabetes mellitus in hypertensive patients: the VALUE trial J Hum Hypertens 2008 22 520 527en_US
dc.identifier.citedreferenceSattar N Scherbakova O Ford I O'Reilly DS Stanley A Forrest E Macfarlane PW Packard CJ Cobbe SM Shepherd J Elevated alanine aminotransferase predicts new‐onset type 2 diabetes independently of classical risk factors, metabolic syndrome, C‐reactive protein in the west of Scotland coronary prevention study Diabetes 2004 53 2855 2860en_US
dc.identifier.citedreferenceFraser A Harris R Sattar N Ebrahim S Davey SG Lawlor DA Alanine aminotransferase, gamma‐glutamyltransferase, incident diabetes: the British Women's Heart, Health Study, meta‐analysis Diabetes Care 2009 32 741 750en_US
dc.identifier.citedreferenceTenenbaum A Motro M Fisman EZ Leor J Boyko V Mandelzweig L Behar S Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis Cardiology 2003 100 207 215en_US
dc.identifier.citedreferenceIannello S Milazzo P Belfiore F Animal and human tissue Na,K‐ATPase in obesity and diabetes: a new proposed enzyme regulation Am J Med Sci 2007 333 1 9en_US
dc.identifier.citedreferenceBagrov YY Manusova NB Frolova EV Egorova IA Kashkin VA Tapilskaya NI Fedorova OV Bagrov AY Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. Preliminary observations and a hypothesis Pathophysiology 2007 14 147 151en_US
dc.identifier.citedreferenceDankner R Abdul‐Ghani MA Gerber Y Chetrit A Wainstein J Raz I Predicting the 20‐year diabetes incidence rate Diabetes Metab Res Rev 2007 23 551 558en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhfhfs067.pdf
Size:
176.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.